Oculus Innovative Sciences, Inc. (OCLS) Announces Allowance of New Patent in Mexico for Novel Solution for Use in Invasive Surgical Procedures
7/2/2013 8:01:25 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PETALUMA, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 27 countries, today announced the allowance of a Mexican patent for the use of the company's novel antimicrobial surgical solution in the treatment and prevention of peritonitis. The imminent issuance of this Mexican patent, expiring in 2027, provides Oculus' Latin American partner, More Pharma, the opportunity to pursue a new drug candidate in Latin America in parallel to Oculus' subsidiary, Ruthigen, Inc.'s, development of the drug for the U.S. market. The novel new formulation, RUT58-60, is an advanced next-generation Microcyn Technology drug candidate specifically engineered for use in invasive surgical procedures, including peritonitis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by